{"classes":[{"categories":[{"measurements":[{"comment":"Upper boundary was not estimated due to the limited number of participants with events.","groupId":"OG000","lowerLimit":"15.83","upperLimit":"NA","value":"17.82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Overall survival is defined as the time from initiation of therapy to death from any cause or last follow-up visit.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine in escalating doses of 50, 70 or 90 mg/m\\^2 as combination therapy with bortezomib at 1.0 mg/m\\^2/dose administered for up to eight 28 day cycles. Participants whose disease has not progressed at the end of the eight cycles will be followed until disease progression or death.","id":"OG000","title":"Bendamustine and Bortezomib - Overall"}],"paramType":"MEDIAN","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"up to 23 months","title":"Kaplan-Meier Estimate for Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}